Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CT.

Journal: Annals of nuclear medicine
Published Date: Jul 15, 2025

Abstract

BACKGROUNDS: Automated PROMISE (aPROMISE), which is an artificial intelligence-supported software for prostate-specific membrane antigen (PSMA) PET/CT based on PROMISE V2, has demonstrated diagnostic utility with better correspondence rates compared to manual diagnosis. However, previous studies have consistently utilized F-PSMA PET/CT. Therefore, we investigated the diagnostic utility of aPROMISE using both F- and  Ga-PSMA PET/CT of Japanese patients with metastatic prostate cancer (mPCa).

Authors

  • Yuki Enei
    Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
  • Takafumi Yanagisawa
    Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan. t.yanagisawa.jikei@gmail.com.
  • Atsuya Okada
    Jinsenkai MI Clinic, Osaka, Japan.
  • Hidetoshi Kuruma
    Bashamichi Sakura Clinic, Yokohama, Japan.
  • Chieko Okazaki
    Theranostics Yokohama, Yokohama, Japan.
  • Ken Watanabe
    Department of Radiology, The Jikei University School of Medicine, Minato-Ku, Tokyo, Japan.
  • Nat P Lenzo
    ICON Cancer Centre, Midland, WA, Australia.
  • Takahiro Kimura
    Department of Urology, Jikei University, Tokyo, Japan.
  • Kenta Miki
    Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals